Clinical Trial Update: PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-05212384 (PKI-587) for therapy-related AML/MDS and de novo/relapsed or refractory AML was terminated. The update indicates the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• PF-05212384 (PKI-587) (PKI-587)

Snippet

Sponsor: Institut Curie | Conditions: Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome, Acute Myeloid Leukemia, in Relapse | Phase 2 | Status: TERMINATED